Загрузка компании
Keep exploring
The themes Palatin Technologies is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,6B $A+
EXELExelixis, Inc.16,8B $A+
JAZZJazz Pharmaceuticals plc15,5B $A
TECHBIO-Techne Corp11,4B $A+
HALOHalozyme Therapeutics, Inc.11,4B $A+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 окт. 2026 г.CBGraded C, now B
MCKMckesson Corporation4 нояб. 2026 г.BAGraded B, now A
CVSCVS Health Corp4 нояб. 2026 г.BAGraded B, now A
EWEdwards Lifesciences Corporation4 нояб. 2026 г.BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 окт. 2026 г.CAGraded C, now A
На чём зарабатывает
- Licensing and research collaborations
Конкурирует с
Что продаёт4
Next-generation long-acting MC4R peptide agonist
An experimental peptide medicine being developed as a once-weekly injection for obesity, with a focus on rare conditions involving appetite and weight regulation.
Next-generation oral MC4R small-molecule agonist
An experimental medicine taken by mouth that Palatin is preparing for further development for rare obesity disorders.
PL9643
An experimental peptide medicine for dry eye disease. Palatin licensed development and commercialization rights to Altanispac Labs.
PL8177
An experimental oral peptide medicine studied for inflammatory bowel diseases, including ulcerative colitis; Palatin is seeking a development partner.
Кто покупает2
- Pharmaceutical companies that license drug candidates or development rights and may pay upfront fees, research funding, milestone payments and royalties.
- Biopharmaceutical partners, including Boehringer Ingelheim and Altanispac Labs, which take responsibility for developing or commercializing licensed programs.
На чём держится и что может это сломать
От чего зависит бизнес
- 1Needs additional funding to carry out research and clinical development; management has identified substantial doubt about its ability to continue as a going concern.
- 2Relies on partners such as Boehringer Ingelheim and Altanispac Labs to advance licensed medicines; payments beyond initial fees depend on future development, regulatory and sales milestones.
- 3Relies on outside manufacturers, suppliers and research organizations for drug materials, manufacturing and studies.
Что может пойти не так
- 1Palatin may be unable to raise the money needed to continue operations and develop its drug candidates.
- 2Its main internally funded obesity candidates are at an early stage, and clinical studies or regulatory review may fail to support their use as medicines.
- 3Partner-led programs may not advance or produce milestone payments and royalties if collaborators do not develop or commercialize the medicines successfully.
Полная финансовая отчётность →
О компании Palatin Technologies Inc.
Palatin's main in-house work targets the melanocortin 4 receptor (MC4R), which is involved in appetite and body weight, with injectable and oral drug candidates for rare obesity disorders. It also develops or licenses medicines aimed at inflammatory diseases, including eye and bowel conditions. Its former approved drug Vyleesi was acquired by Cosette in 2023; Palatin now seeks income from licensing, research funding, milestone payments and, if licensed medicines reach the market, royalties.
- Штаб-квартира
- Princeton, New Jersey, United States
- Год основания
- 1986 (incorporated; biopharmaceutical operations began in 1996)
- Сотрудников
- 25 (September 25, 2026, high)
- Торгуется на
- Nasdaq Capital Market
- Конец финансового года
- June 30
Построено по собственной отчётности Palatin Technologies Inc., поданной в Комиссию по ценным бумагам и биржам США (SEC). Цифры — как отчиталась компания, история на акцию пересчитана на сегодняшнюю базу. Это описание бизнеса — не инвестиционная рекомендация и не совет что-либо покупать или продавать.
